Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06998043 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study With Phage for CF Subjects With Pseudomonas Lung Infection

StatusRecruiting
PhasePhase 2
SponsorBiomX Ltd
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 22, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Secondary endpoints: details revised at 2 of 6 entriesv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 11 to 14
    • Start date changed from estimate of May 2025 to Jul 2, 2025
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twice daily BX004 can reduce the amount of PsA in the sputum compared to placebo (on top of background CF therapy).
Trial Details
NCT Number NCT06998043
Lead Sponsor BiomX Ltd
Conditions
(from sponsor)		 Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
Related terms Cystic Fibrosis
Enrollment 63 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov